NVN Liquidation, Inc.

2023 Q2 Form 10-Q Financial Statement

#000146715423000047 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.54M $35.49M
YoY Change -64.67% 8.67%
Cash & Equivalents $12.54M $35.49M
Short-Term Investments
Other Short-Term Assets $5.193M $5.699M
YoY Change -8.88% 44.28%
Inventory $1.116M $1.478M
Prepaid Expenses
Receivables $13.84M $16.01M
Other Receivables $0.00 $0.00
Total Short-Term Assets $32.69M $58.68M
YoY Change -44.3% 42.51%
LONG-TERM ASSETS
Property, Plant & Equipment $13.52M $13.44M
YoY Change 0.6% 284.8%
Goodwill $4.056M $4.002M
YoY Change 1.35%
Intangibles $27.00M $32.95M
YoY Change -18.07% 43838.67%
Long-Term Investments
YoY Change
Other Assets $195.0K $295.0K
YoY Change -33.9% -8.1%
Total Long-Term Assets $47.11M $53.37M
YoY Change -11.73% 819.33%
TOTAL ASSETS
Total Short-Term Assets $32.69M $58.68M
Total Long-Term Assets $47.11M $53.37M
Total Assets $79.79M $112.0M
YoY Change -28.79% 138.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.32M $4.753M
YoY Change 201.3% 374.83%
Accrued Expenses $18.24M $34.62M
YoY Change -47.32% 1140.82%
Deferred Revenue $2.586M $5.823M
YoY Change -55.59% 94.75%
Short-Term Debt $7.922M $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $43.91M $46.98M
YoY Change -6.52% 447.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $16.50M
YoY Change -100.0% 13650.0%
Other Long-Term Liabilities $482.0K $297.0K
YoY Change 62.29% -64.0%
Total Long-Term Liabilities $482.0K $16.80M
YoY Change -97.13% 1677.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $43.91M $46.98M
Total Long-Term Liabilities $482.0K $16.80M
Total Liabilities $82.62M $106.2M
YoY Change -22.18% 130.13%
SHAREHOLDERS EQUITY
Retained Earnings -$324.4M -$292.3M
YoY Change 10.96% 13.21%
Common Stock $3.000K $2.000K
YoY Change 50.0% -86.67%
Preferred Stock
YoY Change
Treasury Stock (at cost) $155.0K
YoY Change 0.0%
Treasury Stock Shares 950.0 shares
Shareholders Equity -$2.828M $5.882M
YoY Change
Total Liabilities & Shareholders Equity $79.79M $112.0M
YoY Change -28.79% 138.49%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001467154
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-37880
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Novan, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4427682
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
4020 Stirrup Creek Drive, Suite 110
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Durham,
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27703
CY2023Q1 dei City Area Code
CityAreaCode
919
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
485-8080
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
NOVN
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28015371 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12541000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12316000 usd
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
646000 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1047000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13836000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22002000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
1116000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1196000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4547000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5807000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
32686000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
42368000 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
581000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
583000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13521000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13882000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
26998000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
27475000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
195000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
210000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1756000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1756000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
4056000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
4056000 usd
CY2023Q1 us-gaap Assets
Assets
79793000 usd
CY2022Q4 us-gaap Assets
Assets
90330000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
14321000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13689000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18238000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18624000 usd
CY2023Q1 novn Factoring Arrangement Payable Current
FactoringArrangementPayableCurrent
7922000 usd
CY2022Q4 novn Factoring Arrangement Payable Current
FactoringArrangementPayableCurrent
10302000 usd
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2586000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2586000 usd
CY2023Q1 novn Researchand Funding Arrangement Liability Current
ResearchandFundingArrangementLiabilityCurrent
378000 usd
CY2022Q4 novn Researchand Funding Arrangement Liability Current
ResearchandFundingArrangementLiabilityCurrent
555000 usd
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
451000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
465000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
191000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
43910000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
46398000 usd
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
7433000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8079000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3387000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3739000 usd
CY2023Q1 novn Researchand Development Funding Arrangement Liability Noncurrent
ResearchandDevelopmentFundingArrangementLiabilityNoncurrent
0 usd
CY2022Q4 novn Researchand Development Funding Arrangement Liability Noncurrent
ResearchandDevelopmentFundingArrangementLiabilityNoncurrent
25000 usd
CY2023Q1 novn Researchand Development Funding Arrangement Liability Related Parties Noncurrent
ResearchandDevelopmentFundingArrangementLiabilityRelatedPartiesNoncurrent
25000000 usd
CY2022Q4 novn Researchand Development Funding Arrangement Liability Related Parties Noncurrent
ResearchandDevelopmentFundingArrangementLiabilityRelatedPartiesNoncurrent
25000000 usd
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
2353000 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
2037000 usd
CY2023Q1 novn Deferred Tax Liabilities Non Current
DeferredTaxLiabilitiesNonCurrent
56000 usd
CY2022Q4 novn Deferred Tax Liabilities Non Current
DeferredTaxLiabilitiesNonCurrent
0 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
482000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
447000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
82621000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
85725000 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28016321 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24723258 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28015371 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24722308 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
321723000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
315038000 usd
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
950 shares
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
950 shares
CY2023Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
155000 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
155000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-324399000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-310280000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2828000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4605000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79793000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
90330000 usd
CY2023Q1 us-gaap Revenues
Revenues
3166000 usd
CY2022Q1 us-gaap Revenues
Revenues
1928000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1285000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
206000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4832000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4833000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10040000 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9994000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
477000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
121000 usd
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
365000 usd
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
16999000 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
15154000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13833000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13226000 usd
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
30000 usd
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
3000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
277000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
132000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-25000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-230000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-154000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14063000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13380000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
56000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14119000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-14119000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13380000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13380000 usd
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26115986 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26115986 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18829534 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18829534 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4605000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
431000 usd
CY2023Q1 novn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
865000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-14119000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2828000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18319000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
381000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13380000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
5882000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-14119000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13380000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
410000 usd
CY2022Q1 us-gaap Depreciation
Depreciation
97000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
477000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
121000 usd
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-646000 usd
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
365000 usd
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
CY2023Q1 novn Provision For Deferred Income Taxes
ProvisionForDeferredIncomeTaxes
-56000 usd
CY2022Q1 novn Provision For Deferred Income Taxes
ProvisionForDeferredIncomeTaxes
0 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
431000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
381000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8166000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8543000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-80000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-232000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1260000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-565000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
606000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1604000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1106000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
393000 usd
CY2022Q1 novn Proceeds From Factoring Arrangement
ProceedsFromFactoringArrangement
0 usd
CY2023Q1 novn Repayments Of Factoring Arrangement
RepaymentsOfFactoringArrangement
28715000 usd
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2591000 usd
CY2023Q1 novn Increase Decreasein Researchand Development Funding Arrangement Liabilities
IncreaseDecreaseinResearchandDevelopmentFundingArrangementLiabilities
-202000 usd
CY2022Q1 novn Increase Decreasein Researchand Development Funding Arrangement Liabilities
IncreaseDecreaseinResearchandDevelopmentFundingArrangementLiabilities
-297000 usd
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
28000 usd
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
84000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4250000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
766000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
928000 usd
CY2023Q1 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0 usd
CY2022Q1 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
11993000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12921000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5610000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023Q1 novn Proceeds From Factoring Arrangement
ProceedsFromFactoringArrangement
26335000 usd
CY2022Q1 novn Repayments Of Factoring Arrangement
RepaymentsOfFactoringArrangement
0 usd
CY2023Q1 novn Proceeds From Issuance Of Common Stock Under Equity Distribution
ProceedsFromIssuanceOfCommonStockUnderEquityDistribution
865000 usd
CY2022Q1 novn Proceeds From Issuance Of Common Stock Under Equity Distribution
ProceedsFromIssuanceOfCommonStockUnderEquityDistribution
562000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4095000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
562000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-178000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11593000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13946000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47668000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13768000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36075000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
277000 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
45000 usd
CY2023Q1 novn Contingent Consideration From Prior Acquisitions Included In Accrued Expenses Milestones
ContingentConsiderationFromPriorAcquisitionsIncludedInAccruedExpensesMilestones
500000 usd
CY2022Q1 novn Contingent Consideration From Prior Acquisitions Included In Accrued Expenses Milestones
ContingentConsiderationFromPriorAcquisitionsIncludedInAccruedExpensesMilestones
0 usd
CY2023Q1 novn Deferred Offering Costs In Accounts Payable And Accrued Expenses
DeferredOfferingCostsInAccountsPayableAndAccruedExpenses
220000 usd
CY2022Q1 novn Deferred Offering Costs In Accounts Payable And Accrued Expenses
DeferredOfferingCostsInAccountsPayableAndAccruedExpenses
0 usd
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1780000 usd
CY2023Q1 novn Noncash Or Part Noncash Acquisition Contingent Consideration
NoncashOrPartNoncashAcquisitionContingentConsideration
0 usd
CY2022Q1 novn Noncash Or Part Noncash Acquisition Contingent Consideration
NoncashOrPartNoncashAcquisitionContingentConsideration
3773000 usd
CY2023Q1 us-gaap Notes Issued1
NotesIssued1
0 usd
CY2022Q1 us-gaap Notes Issued1
NotesIssued1
16500000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12541000 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35492000 usd
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
646000 usd
CY2022Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
581000 usd
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
583000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13768000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36075000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-324399000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12541000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. The Company reviews all significant estimates affecting the condensed consolidated financial statements on a recurring basis and records the effects of any necessary adjustments prior to their issuance.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates made by management include provisions for product returns, coupons, rebates, chargebacks, trade and cash discounts, allowances and distribution fees paid to certain wholesalers, inventory net realizable value, useful lives of amortizable intangible assets, stock-based compensation, accrued expenses, valuation of assets and liabilities in business combinations, developmental timelines related to licensed products, valuation of notes payable issued in conjunction with the acquisition, valuation of contingent consideration and contingencies. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span></div>
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
141000 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
141000 usd
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. The Company places its cash and cash equivalents with financial institutions and these deposits may at times be in excess of insured limits and the Company assesses the creditworthiness of its customers on an on-going basis.</span></div>
CY2023Q1 us-gaap Advertising Expense
AdvertisingExpense
835000 usd
CY2022Q1 us-gaap Advertising Expense
AdvertisingExpense
387000 usd
CY2022Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2022Q1 us-gaap Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual
BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
1246000 usd
CY2022Q1 us-gaap Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual
BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
-726000 usd
CY2023Q1 novn Milestone Payments Expired
MilestonePaymentsExpired
2 paymentinstallment
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1957000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2037000 usd
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
841000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
841000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
1116000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1196000 usd
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
443000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
410000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
97000 usd
CY2023Q1 novn Prepaid Inventory Deposits
PrepaidInventoryDeposits
1280000 usd
CY2022Q4 novn Prepaid Inventory Deposits
PrepaidInventoryDeposits
1280000 usd
CY2023Q1 novn Prepaid Services Current
PrepaidServicesCurrent
163000 usd
CY2022Q4 novn Prepaid Services Current
PrepaidServicesCurrent
121000 usd
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
936000 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1341000 usd
CY2023Q1 novn Prepaid Prescription Drug User Fee Act Fee Current
PrepaidPrescriptionDrugUserFeeActFeeCurrent
788000 usd
CY2022Q4 novn Prepaid Prescription Drug User Fee Act Fee Current
PrepaidPrescriptionDrugUserFeeActFeeCurrent
1182000 usd
CY2023Q1 novn Product Samples Current
ProductSamplesCurrent
937000 usd
CY2022Q4 novn Product Samples Current
ProductSamplesCurrent
1362000 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
521000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4547000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5807000 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16628000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16590000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3107000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2708000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13521000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13882000 usd
CY2023Q1 novn Lessee Operating Lease Tenant Improvement Allowance
LesseeOperatingLeaseTenantImprovementAllowance
2450000 usd
CY2023Q1 us-gaap Lease Cost
LeaseCost
143000 usd
CY2022Q1 us-gaap Lease Cost
LeaseCost
137000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
457000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
208000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
645000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
665000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
685000 usd
CY2023Q1 novn Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
3016000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5676000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1824000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3852000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1756000 usd
CY2023Q1 novn Total Operating Lease Asset
TotalOperatingLeaseAsset
1756000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
465000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3387000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3852000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
4056000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
4056000 usd
CY2023Q1 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
0 usd
CY2022Q4 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
0 usd
CY2023Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
29075000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2077000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
26998000 usd
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
29075000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1600000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
27475000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1458000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1941000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1935000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1935000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1935000 usd
CY2023Q1 novn Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
17719000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
26923000 usd
CY2023Q1 novn Accrued Rebates Discounts And Chargebacks Current
AccruedRebatesDiscountsAndChargebacksCurrent
6964000 usd
CY2022Q4 novn Accrued Rebates Discounts And Chargebacks Current
AccruedRebatesDiscountsAndChargebacksCurrent
8671000 usd
CY2023Q1 novn Accrued Returns Current
AccruedReturnsCurrent
1667000 usd
CY2022Q4 novn Accrued Returns Current
AccruedReturnsCurrent
3011000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2242000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
937000 usd
CY2023Q1 novn Accrued Outside Research And Development Services Current
AccruedOutsideResearchAndDevelopmentServicesCurrent
157000 usd
CY2022Q4 novn Accrued Outside Research And Development Services Current
AccruedOutsideResearchAndDevelopmentServicesCurrent
410000 usd
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1738000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
542000 usd
CY2023Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
270000 usd
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
675000 usd
CY2023Q1 novn Accrued Working Capital Adjustment Current
AccruedWorkingCapitalAdjustmentCurrent
1000000 usd
CY2022Q4 novn Accrued Working Capital Adjustment Current
AccruedWorkingCapitalAdjustmentCurrent
0 usd
CY2023Q1 novn Accrued Milestones Current
AccruedMilestonesCurrent
2250000 usd
CY2022Q4 novn Accrued Milestones Current
AccruedMilestonesCurrent
1250000 usd
CY2023Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
243000 usd
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
747000 usd
CY2023Q1 novn Accrued Regulatory Activities Current
AccruedRegulatoryActivitiesCurrent
0 usd
CY2022Q4 novn Accrued Regulatory Activities Current
AccruedRegulatoryActivitiesCurrent
165000 usd
CY2023Q1 novn Accrued Collaboration Reimbursement Current
AccruedCollaborationReimbursementCurrent
835000 usd
CY2022Q4 novn Accrued Collaboration Reimbursement Current
AccruedCollaborationReimbursementCurrent
532000 usd
CY2023Q1 novn Accrued Collaboration Deposit Current
AccruedCollaborationDepositCurrent
0 usd
CY2022Q4 novn Accrued Collaboration Deposit Current
AccruedCollaborationDepositCurrent
1149000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
872000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
535000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18238000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18624000 usd
CY2023Q1 novn Factoring Arrangement Payable Current
FactoringArrangementPayableCurrent
7922000 usd
CY2022Q4 novn Factoring Arrangement Payable Current
FactoringArrangementPayableCurrent
10302000 usd
CY2023Q1 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
210000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28015371 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24722308 shares
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14661448 shares
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7327414 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 usd
CY2022Q4 novn Contract With Customer Liability Gross
ContractWithCustomerLiabilityGross
10665000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
10665000 usd
CY2023Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 usd
CY2023Q1 novn Contract With Customer Liability Gross
ContractWithCustomerLiabilityGross
10019000 usd
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
10019000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2586000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8079000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
10665000 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1033370 shares
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2586000 usd
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
7433000 usd
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
10019000 usd
CY2023Q1 novn Revenue From Contract With Customer Estimated Performance Period
RevenueFromContractWithCustomerEstimatedPerformancePeriod
P10Y
CY2020Q1 novn Share Based Compensation Number Of Stock Appreciation Rights Granted
ShareBasedCompensationNumberOfStockAppreciationRightsGranted
60000 shares
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
431000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
381000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
431000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
381000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1032570 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.34
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
15200 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.45
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
14400 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.02
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1033370 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.31
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M2D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q1 novn Milestone Payments Expired
MilestonePaymentsExpired
2 paymentinstallment
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 segment

Files In Submission

Name View Source Status
0001467154-23-000047-index-headers.html Edgar Link pending
0001467154-23-000047-index.html Edgar Link pending
0001467154-23-000047.txt Edgar Link pending
0001467154-23-000047-xbrl.zip Edgar Link pending
exhibit311q12023.htm Edgar Link pending
exhibit312q12023.htm Edgar Link pending
exhibit321q12023.htm Edgar Link pending
exhibit322q12023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
novn-20230331.htm Edgar Link pending
novn-20230331.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
novn-20230331_def.xml Edgar Link unprocessable
novn-20230331_lab.xml Edgar Link unprocessable
novn-20230331_pre.xml Edgar Link unprocessable
novn-20230331_htm.xml Edgar Link completed
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
novn-20230331_cal.xml Edgar Link unprocessable